Table 1—

Clinical characteristics in the intention-to-treat population

PlaceboALA600ALA1200ALA1800
n43454746
Age (years)57 ± 1156 ± 1259 ± 1259 ± 9
Sex (% male)35444041
BMI (kg/m2)29.1 ± 4.428.7 ± 3.930.9 ± 4.528.4 ± 4.8
Systolic blood pressure (mmHg)134 ± 19134 ± 16141 ± 17135 ± 10
Systolic blood pressure (mmHg)81 ± 980 ± 1083 ± 782 ± 9
Heart rate (bpm)73 ± 974 ± 1273 ± 1072 ± 8
Diabetes type (% type 2)84828385
Duration of diabetes (years)14 ± 1013 ± 814 ± 1015 ± 11
Insulin treatment (%)42605357
Treatment with oral antidiabetic agents (%)74676450
A1C (%)7.53 ± 1.187.58 ± 1.097.85 ± 1.317.81 ± 1.14
Smokers (%)*011119
Hypertension (%)61696872
Polyneuropathy stage (% stage 2a)93828998
Duration of neuropathy (years)4.9 ± 3.24.8 ± 3.95.0 ± 3.84.9 ± 4.0
Retinopathy (%)51677574
Nephropathy (%)26201722
  • Data means ± SD unless otherwise indicated.

  • *

    * Smoker within the last 2 years.